Canakinumab
novartis
['canakinumab']
a trial led by our dr. guillermo garcia-manero evaluated the clinical and biological effects of canakinumab in lower-risk patient with myelodysplastic syndromes. garcia-manero shares the phase ii results at #ash22: #endcancer 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789